{"entity":{"id":"paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016","kind":"paper","name":"CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial","aka":[],"tldr":"In 405 Cuban patients with advanced lung cancer, the EGF vaccine CIMAvax-EGF after chemotherapy gave a median survival of 10.8 months against 8.9 with supportive care; the difference was significant only by a weighted test and among patients who had at least four doses.","summary":"Published as \"A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients\". CIMAvax-EGF is human recombinant epidermal growth factor joined to a carrier protein with the adjuvant Montanide ISA51, intended to make the body produce antibodies that block EGF from reaching its receptor. Four to six weeks after first-line chemotherapy, 405 patients with stage IIIB or IV non-small cell lung cancer were randomised to the vaccine or to best supportive care.","asOf":"2026-11-11","links":[{"label":"Clin Cancer Res 2016","url":"https://doi.org/10.1158/1078-0432.CCR-15-0855"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/26927662/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":["cimavax-egf"],"companies":["cimab"],"institutions":["inor-cuba"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2016,"doi":"10.1158/1078-0432.CCR-15-0855","pmid":"26927662","authors":"Rodriguez PC, Popa X, Martínez O, et al.","paperType":"rct","findings":["Median survival in the safety population was 10.83 months with the vaccine and 8.86 months with supportive care (HR 0.82, P = 0.100 by the standard log rank test; P = 0.04 by a weighted log rank test).","Among patients who received at least four doses, median survival was 12.43 against 9.43 months (HR 0.77, P = 0.036).","Vaccinated patients with high baseline EGF concentration had a median survival of 14.66 months; adverse reactions were mostly grade 1 or 2 injection-site pain, fever, vomiting and headache."],"whatItMeans":"The main evidence for Cuba's lung cancer vaccine: well tolerated, with a survival gain that depends on how the analysis is done and that was clearest in patients who completed the induction doses.","caveats":["The standard primary comparison was not statistically significant.","The per-protocol benefit excludes patients who stopped early, which can favour the vaccine arm.","Control patients received supportive care only, not an active maintenance treatment."],"participants":405},"route":"/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"cimavax-egf","kind":"drug","name":"CIMAvax-EGF","route":"/drugs/cimavax-egf/"}],"company":[{"id":"cimab","kind":"company","name":"CIMAB","route":"/companies/cimab/"}],"institution":[{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/"},{"id":"cencec-cuba","kind":"institution","name":"National Coordinating Centre of Clinical Trials, Cuba (CENCEC)","route":"/institutions/cencec-cuba/"}]}}